Cardiol Therapeutics (CRDL) Projected to Post Quarterly Earnings on Monday

Cardiol Therapeutics (NASDAQ:CRDL) is projected to issue its quarterly earnings data before the market opens on Monday, April 7th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter.

Cardiol Therapeutics Stock Down 3.4 %

Cardiol Therapeutics stock opened at $0.96 on Monday. The business’s 50-day moving average price is $1.21 and its 200 day moving average price is $1.53. The company has a quick ratio of 2.49, a current ratio of 2.49 and a debt-to-equity ratio of 0.01. The firm has a market cap of $79.30 million, a price-to-earnings ratio of -2.46 and a beta of 0.95. Cardiol Therapeutics has a 52 week low of $0.91 and a 52 week high of $3.12.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $9.00 target price on shares of Cardiol Therapeutics in a research note on Monday, February 24th. RODMAN&RENSHAW upgraded shares of Cardiol Therapeutics to a “strong-buy” rating in a research report on Tuesday, January 28th. Finally, Rodman & Renshaw began coverage on shares of Cardiol Therapeutics in a research note on Tuesday, January 28th. They set a “buy” rating and a $7.00 target price on the stock. Five research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Cardiol Therapeutics presently has an average rating of “Buy” and an average target price of $8.40.

About Cardiol Therapeutics

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.